Danaher Corporation (DHR) shares plummeted 6.63% in pre-market trading on Wednesday, January 29th, following the company's fourth-quarter 2024 earnings release.
The key reason behind the stock's sharp decline was Danaher's failure to meet Wall Street's profit expectations for the quarter. The company reported adjusted earnings per share of $2.14, narrowly missing the consensus estimate of $2.16. While revenue of $6.54 billion exceeded expectations of $6.42 billion, the slight earnings miss raised concerns among investors about weak demand from the company's biotech and pharmaceutical clients for its tools and services used in drug development.
Danaher's weaker-than-expected performance in the quarter seems to have caught the market off guard, given the company's strong track record of consistently meeting or exceeding earnings estimates in recent years. The disappointing results have sparked doubts about Danaher's ability to sustain its growth momentum, at least in the near term, as it navigates ongoing challenges in the biotech industry.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。